De Smedt Linde, Palmans Sofie, Andel Daan, Govaere Olivier, Boeckx Bram, Smeets Dominiek, Galle Eva, Wouters Jasper, Barras David, Suffiotti Madeleine, Dekervel Jeroen, Tousseyn Thomas, De Hertogh Gert, Prenen Hans, Tejpar Sabine, Lambrechts Diether, Sagaert Xavier
Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Vesalius Research Center, Vlaams instituut voor Biotechnologie (VIB), Leuven, Belgium.
Br J Cancer. 2017 Jan 3;116(1):58-65. doi: 10.1038/bjc.2016.382. Epub 2016 Nov 24.
Tumour budding, described as the presence of single cells or small clusters of up to five tumour cells at the invasive margin, is established as a prognostic marker in colorectal carcinoma. In the present study, we aimed to investigate the molecular signature of tumour budding cells and the corresponding tumour bulk.
Tumour bulk and budding areas were microdissected and processed for RNA-sequencing. As little RNA was obtained from budding cells, a special low-input mRNA library preparation protocol was used. Gene expression profiles of budding as compared with tumour bulk were investigated for established EMT signatures, consensus molecular subtype (CMS), gene set enrichment and pathway analysis.
A total of 296 genes were differentially expressed with an FDR <0.05 and a twofold change between tumour bulk and budding regions. Genes that were upregulated in the budding signature were mainly involved in cell migration and survival while downregulated genes were important for cell proliferation. Supervised clustering according to an established EMT gene signature categorised budding regions as EMT-positive, whereas tumour bulk was considered EMT-negative. Furthermore, a shift from CMS2 (epithelial) to CMS4 (mesenchymal) was observed as tumour cells transit from the tumour bulk to the budding regions.
Tumour budding regions are characterised by a phenotype switch compared with the tumour bulk, involving the acquisition of migratory characteristics and a decrease in cell proliferation. In particular, most tumour budding signatures were EMT-positive and switched from an epithelial subtype (CMS2) in the tumour bulk to a mesenchymal subtype (CMS4) in budding cells.
肿瘤芽生被定义为在浸润边缘存在单个细胞或由多达五个肿瘤细胞组成的小簇,已被确立为结直肠癌的预后标志物。在本研究中,我们旨在探究肿瘤芽生细胞及其相应肿瘤主体的分子特征。
对肿瘤主体和芽生区域进行显微切割,并进行RNA测序。由于从芽生细胞中获得的RNA量很少,因此使用了一种特殊的低输入mRNA文库制备方案。通过已确立的上皮-间质转化(EMT)特征、共识分子亚型(CMS)、基因集富集和通路分析,研究芽生区域与肿瘤主体相比的基因表达谱。
共有296个基因在肿瘤主体和芽生区域之间差异表达,错误发现率(FDR)<0.05且变化倍数为两倍。在芽生特征中上调的基因主要参与细胞迁移和存活,而下调的基因对细胞增殖很重要。根据已确立的EMT基因特征进行的监督聚类将芽生区域分类为EMT阳性,而肿瘤主体被认为是EMT阴性。此外,随着肿瘤细胞从肿瘤主体转移到芽生区域,观察到从CMS2(上皮)向CMS4(间质)的转变。
与肿瘤主体相比,肿瘤芽生区域的特征是表型转换,包括获得迁移特性和细胞增殖减少。特别是,大多数肿瘤芽生特征为EMT阳性,并从肿瘤主体中的上皮亚型(CMS2)转变为芽生细胞中的间质亚型(CMS4)。